EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Group psychedelic therapy: empirical estimates of cost-savings and improved access

Elliot Marseille, Christopher S Stauffer, Manish Agrawal, Paul Thambi, Kimberly Roddy, Michael Mithoefer, Stefano M Bertozzi, James G Kahn

Frontiers in Psychiatry · 06.12.2023 · 14

DOI: 10.3389/fpsyt.2023.1293243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 06.12.2023. Verfasst von Elliot Marseille und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of California, Berkeley, Berkeley, CA, United States. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare group and individual psychedelic-assisted therapy in terms of clinician time, costs and patient access.

Methods

Using 2023 data from two group therapy trial sites, one using 3,4-Methylenedioxymethamphetamine (MDMA) to treat posttraumatic stress disorder (PTSD), and one using psilocybin to treat major depressive disorder (MDD), we compared overall variable costs, clinician costs and clinician time required by therapy protocols utilizing groups versus individual patient therapy. Using published literature, we estimated the prevalence of adults with PTSD and MDD eligible for treatment with psychedelic therapy and projected the savings in time and cost required to treat these prevalent cases.

Results

Group therapy saved 50.9% of clinician costs for MDMA-PTSD and 34.7% for psilocybin-MDD, or $3,467 and $981 per patient, respectively. To treat all eligible PTSD and MDD patients in the U.S. in 10 years with group therapy, 6,711 fewer full-time equivalent (FTE) clinicians for MDMA-PTSD and 1,159 fewer for FTE clinicians for psilocybin-MDD would be needed, saving up to $10.3 billion and $2.0 billion respectively, discounted at 3% annually.

Conclusion

Adopting group therapy protocols where feasible would significantly reduce the cost of psychedelic-assisted therapies. By enhancing the number of patients served per clinician, group therapy could also ameliorate the anticipated shortage of appropriately trained clinicians, thereby accelerating access to these promising new therapies.

Schlagwörter

Stichwörter der Autor:innen

MDMAaccesscosteconomicspsilocybinpsychedelic-assisted therapy

Autor:innen und Institutionen

  • School of Public Health, University of California, Berkeley, Berkeley, CA, United States.
  • Department of Psychiatry, Oregon Health and Science University, Portland, OR, United States.
  • Sunstone Therapies, Rockville, MD, United States.
  • College of Medicine, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States.
  • Institute for Health Policy Sciences, School of Medicine, University of California, San Francisco, San Francisco, CA, United States.

Zitieren

APA

Marseille, E., Stauffer, C. S., Agrawal, M., Thambi, P., Roddy, K., Mithoefer, M., Bertozzi, S. M., & Kahn, J. G. (2023). Group psychedelic therapy: empirical estimates of cost-savings and improved access. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1293243

Vancouver

Marseille E, Stauffer CS, Agrawal M, Thambi P, Roddy K, Mithoefer M, et al. Group psychedelic therapy: empirical estimates of cost-savings and improved access. Frontiers in Psychiatry. 2023;14. doi:10.3389/fpsyt.2023.1293243

BibTeX
@article{Marseille2023,
  author = {Marseille, Elliot and Stauffer, Christopher S and Agrawal, Manish and Thambi, Paul and Roddy, Kimberly and Mithoefer, Michael and Bertozzi, Stefano M and Kahn, James G},
  title = {Group psychedelic therapy: empirical estimates of cost-savings and improved access},
  journal = {Frontiers in Psychiatry},
  year = {2023},
  volume = {14},
  doi = {10.3389/fpsyt.2023.1293243}
}
Kostenlos starten →